Krystal Biotech (NASDAQ:KRYS) Director Sells $192,500.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Daniel Janney sold 700 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $275.00, for a total transaction of $192,500.00. Following the completion of the transaction, the director owned 92,837 shares of the company’s stock, valued at $25,530,175. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Daniel Janney also recently made the following trade(s):

• On Thursday, February 26th, Daniel Janney sold 7,741 shares of Krystal Biotech stock. The stock was sold at an average price of $275.63, for a total value of $2,133,651.83.
• On Tuesday, February 24th, Daniel Janney sold 13,825 shares of Krystal Biotech stock. The shares were sold at an average price of $268.34, for a total value of $3,709,800.50.
• On Tuesday, February 24th, Daniel Janney sold 37,895 shares of Krystal Biotech stock. The stock was sold at an average price of $266.88, for a total value of $10,113,417.60.

Krystal Biotech Stock Down 0.3%

Shares of NASDAQ KRYS opened at $275.64 on Friday. The company has a market cap of $8.06 billion, a P/E ratio of 40.24 and a beta of 0.49. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $298.30. The business has a 50-day simple moving average of $268.99 and a two-hundred day simple moving average of $214.88.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The firm had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KRYS. Hantz Financial Services Inc. lifted its holdings in shares of Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after acquiring an additional 179 shares during the last quarter. Bessemer Group Inc. raised its position in Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares during the period. AdvisorNet Financial Inc bought a new stake in Krystal Biotech in the third quarter worth $30,000. Salomon & Ludwin LLC bought a new stake in Krystal Biotech in the third quarter worth $33,000. Finally, First Horizon Advisors Inc. boosted its position in Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after buying an additional 166 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on KRYS shares. Bank of America boosted their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Jefferies Financial Group lifted their price objective on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. HC Wainwright restated a “buy” rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Chardan Capital raised their price target on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Guggenheim boosted their price objective on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a report on Wednesday. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $326.25.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.